In the past week, ABVC stock has gone up by 54.05%, with a monthly gain of 152.53% and a quarterly surge of 336.30%. The volatility ratio for the week is 21.24%, and the volatility levels for the last 30 days are 12.55% for ABVC BioPharma Inc The simple moving average for the past 20 days is 83.01% for ABVC’s stock, with a 353.74% simple moving average for the past 200 days.
Is It Worth Investing in ABVC BioPharma Inc (NASDAQ: ABVC) Right Now?
The stock has a 36-month beta value of 0.26. Opinions on the stock are mixed, with 0 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for ABVC is 14.55M, and at present, short sellers hold a 3.49% of that float. On July 08, 2025, the average trading volume of ABVC was 417.15K shares.
ABVC stock’s latest price update
The stock price of ABVC BioPharma Inc (NASDAQ: ABVC) has jumped by 28.30% compared to previous close of $3.11. Despite this, the company has seen a gain of 54.05% in its stock price over the last five trading days. globenewswire.com reported 2024-12-11 that FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. (“OncoX”) as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.1
ABVC Trading at 143.26% from the 50-Day Moving Average
After a stumble in the market that brought ABVC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 27.88% of gains for the given period.
Volatility was left at 12.55%, however, over the last 30 days, the volatility rate increased by 21.24%, as shares surge +166.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +355.48% upper at present.
During the last 5 trading sessions, ABVC rose by +54.05%, which changed the moving average for the period of 200-days by +490.24% in comparison to the 20-day moving average, which settled at $2.18. In addition, ABVC BioPharma Inc saw 429.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
N/A, the N/A of ABVC BioPharma Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for ABVC
Current profitability levels for the company are sitting at:
- -3.84% for the present operating margin
- 1.0% for the gross margin
The net margin for ABVC BioPharma Inc stands at -3.56%. The total capital return value is set at -0.24%. Equity return is now at value -27.00%, with -12.26% for asset returns.
Based on ABVC BioPharma Inc (ABVC), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -0.75. The debt to equity ratio resting at 0.4. The interest coverage ratio of the stock is -5.37.
Currently, EBITDA for the company is -4.34 million with net debt to EBITDA at -1.21. When we switch over and look at the enterprise to sales, we see a ratio of 137.25. The receivables turnover for the company is 0.95for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.22.
Conclusion
To sum up, ABVC BioPharma Inc (ABVC) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
